# Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction

> **NCT06362395** · PHASE3 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 114 (estimated)

## Conditions studied

- Liver Metastases

## Interventions

- **RADIATION:** Magnetic resonance (MR)-guided stereotactic ablative single-fraction (SBRT)

## Key facts

- **NCT ID:** NCT06362395
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-05
- **Primary completion:** 2031-09
- **Final completion:** 2031-09
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06362395

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06362395, "Ultra-high Dose Radiation for Liver Metastasis Using MR-guided TReatment With Stereotactic Ablative Single-fraction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06362395. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*